Aimmune to Present at RBC Capital Markets Global Healthcare Conference

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its Chief Financial Officer, Eric Bjerkholt, will present
at the RBC Capital Markets Global Healthcare Conference on Tuesday, May
21, 2019, at 2:35 p.m. E.T. in New York City.

A live webcast of the presentation will be accessible on the Events page
under the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay will also be available following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
oral treatments for life-threatening food allergies. The company’s Characterized
Oral Desensitization
ImmunoTherapy
(CODIT™) approach is intended to provide meaningful levels of protection
against allergic reactions resulting from exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product, AR101, is being
developed as a treatment to reduce the frequency and severity and
adverse events, including anaphylaxis, following exposure to peanut. The
BLA for AR101 is under review by the FDA, which in 2015 granted AR101
Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4 to 17 years of age. Aimmune expects to file
for marketing approval of AR101 in Europe in mid-2019. Aimmune has filed
an IND application for its second product, AR201 for the treatment of
egg allergy, and intends to start a randomized phase 2 clinical trial in
mid-2019. For more information, please see www.aimmune.com.

Contacts

Investors:
Eric Bjerkholt
(650) 376-5582 or
[email protected]

Media:
Jerica
Pitts
(312) 858-3469 or
[email protected]